128 related articles for article (PubMed ID: 11603509)
1. Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse.
Madsen KL
Clin Invest Med; 2001 Oct; 24(5):250-7. PubMed ID: 11603509
[TBL] [Abstract][Full Text] [Related]
2. Probiotic bacteria enhance murine and human intestinal epithelial barrier function.
Madsen K; Cornish A; Soper P; McKaigney C; Jijon H; Yachimec C; Doyle J; Jewell L; De Simone C
Gastroenterology; 2001 Sep; 121(3):580-91. PubMed ID: 11522742
[TBL] [Abstract][Full Text] [Related]
3. Lessons from genetic models of inflammatory bowel disease.
Podolsky DK
Acta Gastroenterol Belg; 1997; 60(2):163-5. PubMed ID: 9260328
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse--a model mimicking inflammatory bowel disease.
Holgersen K; Kvist PH; Markholst H; Hansen AK; Holm TL
J Crohns Colitis; 2014 Feb; 8(2):147-60. PubMed ID: 23994255
[TBL] [Abstract][Full Text] [Related]
5. DHA protects against experimental colitis in IL-10-deficient mice associated with the modulation of intestinal epithelial barrier function.
Zhao J; Shi P; Sun Y; Sun J; Dong JN; Wang HG; Zuo LG; Gong JF; Li Y; Gu LL; Li N; Li JS; Zhu WM
Br J Nutr; 2015 Jul; 114(2):181-8. PubMed ID: 26104043
[TBL] [Abstract][Full Text] [Related]
6. Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs.
Sydora BC; Tavernini MM; Wessler A; Jewell LD; Fedorak RN
Inflamm Bowel Dis; 2003 Mar; 9(2):87-97. PubMed ID: 12769442
[TBL] [Abstract][Full Text] [Related]
7. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis.
Ewaschuk J; Endersby R; Thiel D; Diaz H; Backer J; Ma M; Churchill T; Madsen K
Hepatology; 2007 Sep; 46(3):841-50. PubMed ID: 17659579
[TBL] [Abstract][Full Text] [Related]
8. Posttranslational inhibition of proinflammatory chemokine secretion in intestinal epithelial cells: implications for specific IBD indications.
Hörmannsperger G; Clavel T; Hoffmann M; Reiff C; Kelly D; Loh G; Blaut M; Hölzlwimmer G; Haller D
J Clin Gastroenterol; 2010 Sep; 44 Suppl 1():S10-5. PubMed ID: 20562631
[TBL] [Abstract][Full Text] [Related]
9. IL-10 gene-deficient mice lack TGF-beta/Smad-mediated TLR2 degradation and fail to inhibit proinflammatory gene expression in intestinal epithelial cells under conditions of chronic inflammation.
Ruiz PA; Shkoda A; Kim SC; Sartor RB; Haller D
Ann N Y Acad Sci; 2006 Aug; 1072():389-94. PubMed ID: 17057220
[TBL] [Abstract][Full Text] [Related]
10. Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease.
Reiff C; Delday M; Rucklidge G; Reid M; Duncan G; Wohlgemuth S; Hörmannsperger G; Loh G; Blaut M; Collie-Duguid E; Haller D; Kelly D
Inflamm Bowel Dis; 2009 Nov; 15(11):1721-36. PubMed ID: 19639558
[TBL] [Abstract][Full Text] [Related]
11. Role of bacteria in experimental colitis.
Guarner F; Malagelada JR
Best Pract Res Clin Gastroenterol; 2003 Oct; 17(5):793-804. PubMed ID: 14507589
[TBL] [Abstract][Full Text] [Related]
12. Microbial-host interactions in inflammatory bowel diseases and experimental colitis.
Sartor RB
Nestle Nutr Workshop Ser Pediatr Program; 2009; 64():121-32; discussion 132-7, 251-7. PubMed ID: 19710519
[TBL] [Abstract][Full Text] [Related]
13. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy.
Merga Y; Campbell BJ; Rhodes JM
Dig Dis; 2014; 32(4):475-83. PubMed ID: 24969297
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora.
Madsen KL; Malfair D; Gray D; Doyle JS; Jewell LD; Fedorak RN
Inflamm Bowel Dis; 1999 Nov; 5(4):262-70. PubMed ID: 10579119
[TBL] [Abstract][Full Text] [Related]
15. Understanding why probiotic therapies can be effective in treating IBD.
Fedorak RN
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S111-5. PubMed ID: 18806699
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a novel IL-10 deficient cell transfer model for colitis.
Ikenoue Y; Tagami T; Murata M
Int Immunopharmacol; 2005 Jun; 5(6):993-1006. PubMed ID: 15829415
[TBL] [Abstract][Full Text] [Related]
17. 5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice.
Narushima S; DiMeo D; Tian J; Zhang J; Liu D; Berg DJ
Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G477-88. PubMed ID: 18048478
[TBL] [Abstract][Full Text] [Related]
18. Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse.
Sydora BC; Macfarlane SM; Walker JW; Dmytrash AL; Churchill TA; Doyle J; Fedorak RN
Inflamm Bowel Dis; 2007 Aug; 13(8):947-54. PubMed ID: 17427241
[TBL] [Abstract][Full Text] [Related]
19. Association with selected bacteria does not cause enterocolitis in IL-10 gene-deficient mice despite a systemic immune response.
Sydora BC; Tavernini MM; Doyle JS; Fedorak RN
Dig Dis Sci; 2005 May; 50(5):905-13. PubMed ID: 15906767
[TBL] [Abstract][Full Text] [Related]
20. Human adipose-derived stem cells attenuate inflammatory bowel disease in IL-10 knockout mice.
Jung WY; Kang JH; Kim KG; Kim HS; Jang BI; Park YH; Song IH
Tissue Cell; 2015 Feb; 47(1):86-93. PubMed ID: 25544730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
